IRIS PubliCatt

De Sanctis, Roberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.495
NA - Nord America 1.329
AS - Asia 503
AF - Africa 20
SA - Sud America 10
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 3
Totale 3.364
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.304
IT - Italia 468
SE - Svezia 293
DE - Germania 244
SG - Singapore 205
IE - Irlanda 129
CN - Cina 128
FR - Francia 63
ID - Indonesia 61
RU - Federazione Russa 55
GB - Regno Unito 50
FI - Finlandia 47
IN - India 35
UA - Ucraina 21
CA - Canada 18
ES - Italia 16
NL - Olanda 16
CZ - Repubblica Ceca 15
TR - Turchia 15
IR - Iran 14
BE - Belgio 13
MK - Macedonia 12
HK - Hong Kong 11
CI - Costa d'Avorio 10
RS - Serbia 9
CH - Svizzera 8
EG - Egitto 8
PL - Polonia 7
BR - Brasile 6
IL - Israele 6
JP - Giappone 6
RO - Romania 6
LT - Lituania 5
PA - Panama 5
PT - Portogallo 5
KR - Corea 4
SK - Slovacchia (Repubblica Slovacca) 4
AT - Austria 3
PH - Filippine 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AU - Australia 2
BT - Bhutan 2
CO - Colombia 2
HR - Croazia 2
NZ - Nuova Zelanda 2
PK - Pakistan 2
SA - Arabia Saudita 2
ZA - Sudafrica 2
AL - Albania 1
AR - Argentina 1
BD - Bangladesh 1
CL - Cile 1
DK - Danimarca 1
GL - Groenlandia 1
GR - Grecia 1
HU - Ungheria 1
KZ - Kazakistan 1
MX - Messico 1
MY - Malesia 1
QA - Qatar 1
TH - Thailandia 1
TW - Taiwan 1
VN - Vietnam 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 3.364
Salva come PNG Salva come JPEG
Città #
Chandler 323
Ashburn 202
Singapore 157
Dublin 101
New York 85
Rome 84
Milan 77
Jakarta 61
San Mateo 38
Helsinki 36
Marseille 33
Moscow 30
Princeton 28
Boston 26
Palermo 23
Ann Arbor 19
Los Angeles 19
Dearborn 18
Bremen 17
Wilmington 17
Houston 16
Beijing 15
Cattolica 14
Nanjing 14
Nürnberg 14
Brno 13
Falkenstein 13
Brussels 12
Pune 12
Augusta 11
Kish 11
Munich 11
Paris 11
Abidjan 10
Jacksonville 10
Lancaster 10
Redwood City 10
Salamanca 10
Skopje 10
Toronto 10
Bologna 9
Bari 8
Menlo Park 8
Seattle 8
Turin 8
Andover 7
Boardman 7
Hebei 7
Hong Kong 7
London 7
Shanghai 7
Woodbridge 7
Changsha 6
Izmir 6
Leawood 6
Niš 6
Redmond 6
San Francisco 6
Shenyang 6
Washington 6
Amsterdam 5
Cairo 5
Genoa 5
Lawrence 5
Nanchang 5
Norwalk 5
Stockholm 5
Wandsworth 5
Bitonto 4
Brindisi 4
Chicago 4
Fairfield 4
Fort Worth 4
Frankfurt am Main 4
Guangzhou 4
Jinan 4
Lisbon 4
Monza 4
Mountain View 4
Naaldwijk 4
Palagiano 4
Reggio Calabria 4
Santa Clara 4
Caorle 3
Florence 3
Foggia 3
Grottaferrata 3
Gunzenhausen 3
Istanbul 3
Jiaxing 3
Lappeenranta 3
Messina 3
Neded 3
Ottawa 3
Pulsano 3
Ronciglione 3
San Diego 3
Secaucus 3
Seoul 3
Spoleto 3
Totale 1.920
Salva come PNG Salva come JPEG
Nome #
Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy 258
Oral and Swallowing Abilities Tool (OrSAT) for Type 1 SMA Patients: Development of a New Module 220
Oral and Swallowing Abilities Tool (OrSAT) in nusinersen treated patients 114
Revised upper limb module for spinal muscular atrophy: Development of a new module 100
Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience 90
Predominant distal muscle involvement in spinal muscular atrophy 87
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening 81
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 79
Developmental milestones in type I spinal muscular atrophy 79
Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study 77
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 76
Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy 72
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 72
Developmental milestones in type I spinal muscular atrophy 70
Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data 69
Revised north star ambulatory assessment for young boys with Duchenne muscular dystrophy 67
Longitudinal assessments in discordant twins with SMA 67
Assessing floppy infants: a new module 66
Type I SMA “new natural history”: long-term data in nusinersen-treated patients 62
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies 61
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy 60
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 58
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 57
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 57
Nusinersen in type 0 spinal muscular atrophy: should we treat? 56
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy 54
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 52
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 51
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy 51
De novo partial 13q22-q34 trisomy with typical neurological and immunological findings: A case report with new genetic insights 51
Clinical Variability in Spinal Muscular Atrophy Type III. 51
Development of an academic disease registry for spinal muscular atrophy 48
Type I Spinal Muscular Atrophy patients treated with nusinersen: 4 year follow-up of motor, respiratory and bulbar function 47
Reply to: The need for evidence-based treatment decisions in spinal muscular atrophy type 0 45
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 44
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 43
Revised upper limb module for spinal muscular atrophy: 12 month changes 42
Revised upper limb module for spinal muscular atrophy: Development of a new module 41
Risdiplam in Type 1 Spinal Muscular Atrophy 40
Longitudinal natural history of type I spinal muscular atrophy: A critical review 40
Point-of-care lung and diaphragm ultrasound in a patient with spinal muscular atrophy with respiratory distress type 1 40
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 36
Sleep disorders in spinal muscular atrophy 34
Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey? 34
Needleless inhaled anesthesia with sevoflurane: Advantages of a simplified approach for children with spinal muscular atrophy undergoing intrathecal administration of nusinersen 31
An observational study of functional abilities in infants, children, and adults with type 1 SMA 31
Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome? 30
An observational study of functional abilities in infants, children, and adults with type 1 SMA 30
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability? 28
Gain and loss of upper limb abilities in Duchenne muscular dystrophy patients: A 24-month study 26
Long term follow-up of scoliosis progression in type II SMA patients 23
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 23
An observational study of functional abilities in infants, children, and adults with type 1 SMA 23
Can the CHOP-INTEND be used as An Outcome Measure in the First Months of Age? Implications for Clinical Trials and Real World Data 23
Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study (Neurology and Therapy, (2023), 12, 2, (543-557), 10.1007/s40120-023-00444-1) 20
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 18
Erratum: Long term natural history data in ambulant boys with duchenne muscular dystrophy: 36-month changes (PLoS ONE (2015) 10:12 (e0144079)) 16
Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool 16
Early treatment of type II SMA slows rate of progression of scoliosis 15
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability? 15
Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test 13
Hammersmith Functional Motor Scale and Motor Function Measure-20 in non ambulant SMA patients 13
Ultrasound assessment of diaphragmatic function in type 1 spinal muscular atrophy 12
Upper limb function changes over 12 months in untreated SMA II and III individuals: an item-level analysis using the Revised Upper Limb Module 10
Long‐term natural history in type II and III spinal muscular atrophy: a 4‐year international study on the Hammersmith Functional Motor Scale Expanded 9
Prognostic factors for tube feeding in type I SMA patients treated with disease-modifying therapies: a cohort study 8
Changes in abilities over the initial 12 months of nusinersen treatment for type II SMA 3
Therapeutic Role of Nusinersen on Respiratory Progression in Pediatric Patients With Spinal Muscular Atrophy Type 2 and Nonambulant Type 3 3
Totale 3.438
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.958
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.958
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202089 0 0 0 0 0 18 18 8 9 5 26 5
2020/202175 2 8 2 2 9 9 8 2 9 0 23 1
2021/2022398 13 6 5 72 28 11 9 63 26 19 73 73
2022/20231.124 99 149 65 158 76 138 70 98 157 19 54 41
2023/2024970 34 158 33 86 50 165 151 54 19 47 79 94
2024/2025460 41 24 104 82 132 77 0 0 0 0 0 0
Totale 3.438